NCT04086758

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

A Phase 1 Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Astellas Pharma China, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Conditions

• Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Interventions

Type	Name	Description
DRUG	zolbetuximab	Zolbetuximab will be administered as a 2-hour intravenous infusion

Timeline

• Start date: 2019-10-18
• Primary completion: 2021-01-22
• Completion: 2021-01-22
• First posted: 2019-09-12
• Last updated: 2024-11-20

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study